Some cancer patients react very badly to commonly used chemotherapies — but there is a test that can identify those patients. So why isn't this test being used? This is the question currently being ...

Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.

The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine, are the cornerstone of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with numerous side ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...